BioLife Solutions Inc (BLFS)
Cash ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | US$ in thousands | 95,386 | 23,977 | 22,014 | 29,694 | 27,896 | 19,235 | 21,400 | 19,105 | 19,442 | 27,036 | 24,001 | 59,463 | 69,860 | 75,098 | 76,246 | 89,012 | 90,403 | 93,984 | 29,900 | 6,400 |
| Short-term investments | US$ in thousands | 9,198 | 15,323 | 14,886 | 16,406 | 16,893 | 22,965 | 26,700 | 37,795 | 44,658 | 35,064 | 22,999 | — | 40 | — | 5,872 | — | 5,872 | 3,610 | — | — |
| Total current liabilities | US$ in thousands | 32,734 | 32,166 | 30,819 | 38,658 | 42,178 | 42,622 | 39,587 | 47,319 | 44,582 | 40,418 | 36,369 | 37,752 | 42,700 | 35,793 | 31,275 | 16,381 | 15,573 | 8,362 | 7,490 | 25,460 |
| Cash ratio | 3.19 | 1.22 | 1.20 | 1.19 | 1.06 | 0.99 | 1.22 | 1.20 | 1.44 | 1.54 | 1.29 | 1.58 | 1.64 | 2.10 | 2.63 | 5.43 | 6.18 | 11.67 | 3.99 | 0.25 |
December 31, 2024 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($95,386K
+ $9,198K)
÷ $32,734K
= 3.19
The cash ratio of BioLife Solutions Inc has shown fluctuating trends over the past few years, indicating variations in the company's liquidity position. The cash ratio, which measures the company's ability to cover its current liabilities with its cash and cash equivalents, started at a relatively low level of 0.25 as of March 31, 2020. However, it saw a significant increase to 11.67 by September 30, 2020, suggesting a substantial improvement in the company's ability to meet its short-term obligations with cash on hand.
Subsequently, the cash ratio experienced some fluctuations, hovering between 1.58 and 1.20 in the following quarters until December 31, 2022. This range suggests that BioLife Solutions Inc maintained a moderate level of liquidity during this period. However, the cash ratio decreased to 0.99 by September 30, 2023, which may indicate a temporary liquidity strain for the company.
Despite this dip, the cash ratio recovered slightly in the subsequent quarters, stabilizing around 1.20 to 1.22 until December 31, 2024. This improvement suggests that the company managed to bolster its liquid assets to better cover its short-term liabilities.
Overall, the cash ratio analysis indicates that BioLife Solutions Inc has generally maintained a decent liquidity position, although there have been some fluctuations over the years. It is crucial for the company to closely monitor its cash reserves to ensure it can efficiently meet its financial obligations as they become due.
Peer comparison
Dec 31, 2024